High-throughput automation in next-generation sequencing for the detection of minimum residual disease in liquid biopsies

In this presentation, Lubaina shares an in-depth overview of the clinical validation of a high-throughput plasma whole genome sequencing assay for liquid biopsies, developed at the Ontario Institute for Cancer Research (OICR), Toronto, Canada. The talk explores the challenges of detecting circulating tumor DNA (ctDNA) in low tumor fraction settings and outlines the unique genome-wide mutational integration approach used in the study. Lubina also touches on recent innovations in the field, including methylation analysis, and multimodal biomarker integration.